

Clinical trials of serelaxin

TrialResults-center www.trialresultscenter.org

1 heart failure

| Trial | Treatments | Patients | Trials design and methods |
|---|---|--|---------------------------------|
| serelaxin vs placebo | | | |
| Pre-RELAX-AHF , 2009 [NCT00520806] n=172/62 follow-up: | intravenous relaxin for 48 hours: 10g/kg daily, 30g/kg daily, 100g/kg daily, 250g/kg daily versus placebo | Patients hospitalized with acute heart failure | Parallel groups double blind |

More details and results :

- relaxine for heart failure in acute heart failure at <http://www.trialresultscenter.org/go-Q287>

References

Pre-RELAX-AHF, 2009:

Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;: [19329178]

2 acute heart failure

| Trial | Treatments | Patients | Trials design and methods |
|---|---|--|---------------------------------|
| serelaxin vs placebo | | | |
| Pre-RELAX-AHF , 2009 [NCT00520806] n=172/62 follow-up: | intravenous relaxin for 48 hours: 10g/kg daily, 30g/kg daily, 100g/kg daily, 250g/kg daily versus placebo | Patients hospitalized with acute heart failure | Parallel groups double blind |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---------------------------|
| RELAX-AHF , 2013 [NCT00520806] n=NA follow-up: | 48-h intravenous infusions of placebo or serelaxin (30 g/kg per day) within 16 h from presentation versus placebo (on top standard care) | patients admitted to hospital for acute heart failure | |
| RELAX-AHF-2 <i>ongoing</i> [NCT01870778] n=NA follow-up: | - | Acute Heart Failure Patients | |

More details and results :

- new drug under development for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q640>
- relaxin for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q646>

References

Pre-RELAX-AHF, 2009:

Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. *Lancet* 2009;: [19329178]

RELAX-AHF, 2013:

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, S Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. *Lancet* 2013 Jan 5;381:29-39 [23141816] 10.1016/S0140-6736(12)61855-8

RELAX-AHF-2, :

ongoing trial NCT01870778